4//SEC Filing
PLx Pharma Inc. 4
Accession 0001144204-17-021383
CIK 0001497504operating
Filed
Apr 19, 8:00 PM ET
Accepted
Apr 20, 9:17 PM ET
Size
11.2 KB
Accession
0001144204-17-021383
Insider Transaction Report
Form 4
PLx Pharma Inc.PLXP
MOSSMAN GARY L
Other
Transactions
- Award
Common Stock
2017-04-19+70,982→ 70,982 total - Award
Common Stock
2017-04-19+2,009→ 2,009 total(indirect: By Spouse) - Award
Common Stock
2017-04-19+14,955→ 14,955 total(indirect: By Mossman Partners) - Award
Options
2017-04-19+69,755→ 69,755 totalExercise: $12.44Exp: 2025-07-22→ Common Stock (69,755 underlying)
Footnotes (5)
- [F1]Received in exchange for 90,130 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
- [F2]Received in exchange for 18,989 shares of common stock of PLx Opco Inc. in connection with the Merger.
- [F3]Received in exchange for 2,552 shares of common stock of PLx Opco Inc. in connection with the Merger. The Reporting Person disclaims beneficial ownership of these shares.
- [F4]Received in connection with the Merger in exchange for an employee stock option to buy 88,571 shares of PLx Opco Inc. common stock for $9.80 per share.
- [F5]The option is exercisable as to 51,754 shares as of the date hereof, and will become exercisable as to an additional 18,001 shares on July 22, 2017 (generally subject to continued employment or consulting relationship through such date).
Documents
Issuer
PLx Pharma Inc.
CIK 0001497504
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001497504
Filing Metadata
- Form type
- 4
- Filed
- Apr 19, 8:00 PM ET
- Accepted
- Apr 20, 9:17 PM ET
- Size
- 11.2 KB